Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

A study has found that convenient access to a nearby major park in young adulthood may improve cardiovascular health in midlife.

Academic detailing interventions significantly improved more than half of evidence-based prescribing outcomes.

In nulliparous pregnant individuals, higher radon exposure is associated with greater odds of gestational diabetes (GD).

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Hallmark symptoms of Cushing disease, including abdominal striae and facial rounding, were more common among younger patients than older patients.

There are racial and sex disparities in the discussion of and progression to metabolic and bariatric surgery (MBS) among eligible patients.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Adiponectin levels were associated with increased likelihood of metabolic health improvements and lower risk for diabetes across 6 years.

President Donald Trump's administration has placed a freeze on information being released from government health agencies.